APP and Cognitive impairment: In rodent models of Alzheimer’s disease (e.g., APP/PS1 and 5xFAD), butyrate administration has been shown to reverse Aβ-induced cognitive impairment by restoring hippocampal BDNF expression and activating downstream CREB/TrkB signaling pathways [73].